Recent News

• 04.26.2025 - IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
• 03.25.2025 - IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
• 03.04.2025 - IO Biotech Reports 2024 Business Highlights
• 02.23.2025 - IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
• 02.20.2025 - IO Biotech to Present at the 45th Annual Cowen Health Care Conference
• 02.04.2025 - IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Recent Filings

• 04.25.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.25.2025 - ARS Annual Report to Security Holders
• 04.25.2025 - DEF 14A Other definitive proxy statements
• 04.07.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]